Amrutanjan Health Care Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹141Cr
- +14.6% YoY
- +19.5% QoQ
- Net profit
- ₹19Cr
- 0% YoY
- +35.7% QoQ
- Margin
- 18%
- −1 pp YoY
- +4 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Amrutanjan Health Care Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY26 Revenue from Operations: Rs. 141.03 Cr, up 14.90% YoY (Q3 FY25: Rs. 122.75 Cr). EBITDA for Q3 FY26: Rs. 34.12 crore, a 13.0% increase YoY (Q3 FY25: Rs. 30.22 crore) [Page 29].
From Amrutanjan Health Care Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY26 Revenue from Operations: Rs. 141.03 Cr, up 14.90% YoY (Q3 FY25: Rs. 122.75 Cr)
- Gross Sales - OTC (Q3 FY26): Rs. 148.33 Cr, up 12.48% YoY (Q3 FY25: Rs. 131.87 Cr)
- Net Sales - OTC (Q3 FY26): Rs. 137.22 Cr, up 16.43% YoY (Q3 FY25: Rs. 117.86 Cr)
- Net Sales - Comfy (Q3 FY26): Rs. 36.68 Cr, up 22.55% YoY (Q3 FY25: Rs. 29.93 Cr)
- Beverage Gross Sales (Q3 FY26): Rs. 3.64 Cr, down from Rs. 5.54 Cr in Q3 FY25
- Q3 FY26 Profit Before Tax: Rs. 26.36 Cr (minimal growth YoY)
2 more points from Amrutanjan Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Amrutanjan Health Care Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Amrutanjan Health Care Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 141 | 123 | +14.6% | 118 | +19.5% |
| Operating profit (EBITDA) | 25 | 23 | +8.7% | 17 | +47.1% |
| Operating margin | 18% | 19% | -1 pp | 14% | +4 pp |
| Profit before tax | 26 | 26 | 0% | 19 | +36.8% |
| Net profit (PAT) | 19 | 19 | 0% | 14 | +35.7% |
| EPS (₹) | 6.73 | 6.66 | +1.1% | 4.83 | +39.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Healt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q3 FY26 results?
Q3 FY26 Revenue from Operations: Rs. 141.03 Cr, up 14.90% YoY (Q3 FY25: Rs. 122.75 Cr). EBITDA for Q3 FY26: Rs. 34.12 crore, a 13.0% increase YoY (Q3 FY25: Rs. 30.22 crore) [Page 29].
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
